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Abstract
Retinal visual prostheses (‘‘bionic eyes’’) have the potential to restore vision to blind
or profoundly vision-impaired patients. The medical bionic technology used to
design, manufacture and implant such prostheses is still in its relative infancy, with
various technologies and surgical approaches being evaluated. We hypothesised
that a suprachoroidal implant location (between the sclera and choroid of the eye)
would provide significant surgical and safety benefits for patients, allowing them to
maintain preoperative residual vision as well as gaining prosthetic vision input from
the device. This report details the first-in-human Phase 1 trial to investigate the use
of retinal implants in the suprachoroidal space in three human subjects with end-
stage retinitis pigmentosa. The success of the suprachoroidal surgical approach
and its associated safety benefits, coupled with twelve-month post-operative
efficacy data, holds promise for the field of vision restoration.
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Introduction
Blindness is one of the most feared and debilitating physical disabilities [1], with
the World Health Organisation estimating that 285 million people worldwide
have vision impairment and 39 million people are blind [2]. Recent technological
advances have allowed the development of visual prostheses, or ‘‘bionic eyes’’,
which use implanted electrodes within the visual pathway to restore rudimentary
vision to those with severe vision loss [3, 4]. The success of these technologies has
been such that two devices are now commercially available, with European CE
mark approval being granted to the Argus II device (Second Sight Medical
Products, USA) in 2011 followed by FDA approval in early 2013, and the Alpha
IMS device (Retina Implant AG, Germany) gaining CE mark approval in mid-
2013. These advances have provided proof of concept for the field of vision
restoration, and brought hope to millions of people who have lost their sight from
disease or trauma.
Visual prostheses work by using implanted electrodes to stimulate neurons in
the visual pathway with electrical current via an implanted stimulator [5, 6] or
independent microphotodiode-amplifier-electrode elements [7, 8]. The majority
of visual prostheses developed to date use electrodes implanted within or near the
retina to directly stimulate the inner retinal neurons, bypassing the non-
functioning or dead photoreceptors, and utilizing the intact posterior visual
pathway to transmit signals to the visual cortex. Thus, retinal prostheses require a
relatively intact inner retinal layer to be beneficial, such as seen in retinal
degenerative diseases like retinitis pigmentosa (RP) [9]. RP accounts for over 1.5
million cases of blindness and is the most common form of inherited blindness
[10]. RP causes degeneration of vision over varying time periods and primarily
targets the photoreceptor cells in the outer retina, with anatomical and retinal
imaging studies showing that the inner retinal neurons are relatively preserved in
these people [9, 11–13].
Previous work has shown that retinal prostheses in the epiretinal, subretinal
and intra-scleral locations (Fig. 1) can provide patients with perceptions of light
and basic object recognition, with some recipients even able to read large print
[7, 8, 14–19]. However, there have been some challenges with previous approaches
including issues with stability of the implant, conjunctival and scleral erosions,
retinal detachment, hypotony and endophthalmitis [15, 20, 21]. Many of these
complications are related to the device location and required implantation
procedures, which include vitrectomy (removal of the gel-like vitreous humour
from within the eye) and highly technical surgical techniques. Such adverse events
can lead to poor vision outcomes, loss of residual vision or the need for revision/
removal surgery.
The aim of this study was to develop a less invasive, more anatomically stable
implantation position, by placing the array between the firm fibrous sclera and the
outer retina/choroid, in the suprachoroidal space (Fig. 1C).
One of the main benefits with this location is that the surgical placement is less
technically challenging and does not breach the retinal tissue, negating the need
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for a vitrectomy or incisions into the retina itself. The main disadvantage with this
location is that the electrodes are 250 to 400 mm further away from the target
retinal ganglion cells than in an epiretinal implant [22]. However, our group has
shown in a preclinical feline model that not only is the suprachoroidal surgical
approach feasible, reproducible and safe [23], the prosthesis is biocompatible,
mechanically stable [24] and the electrode array is efficacious, with the ability to
produce cortical responses within acceptable stimulation safety parameters
[25, 26]. There have also been human studies showing that intra-scleral electrodes,
which are implanted even further from the ganglion cells, are able to safely evoke
phosphenes in patients with end-stage retinal degeneration at levels of stimulation
considered to be safe for platinum electrodes [16].
This report describes the first human phase 1 clinical trial (clinicaltrials.gov,
NCT01603576), involving three participants implanted with a retinal prosthesis in
the suprachoroidal space. This study was designed as a proof of concept, first-in-
human trial of the suprachoroidal implant. To allow for maximum flexibility in
device stimulation, a percutaneous connector was used to allow direct stimulation
of the intraocular electrode array, with no implantable electronics used. The
percutaneous connector has previously been used in cochlear implant studies [27]
and requires similar surgical procedures as the implantation of a bone-anchored
Fig. 1. Potential anatomical locations for retinal prosthesis implantation. To date, clinical trials have been
performed with devices in the A: epiretinal position [15], B: subretinal space [7] and D: intrascleral space [19].
Image modified with permission from Bionic Vision Australia.
doi:10.1371/journal.pone.0115239.g001
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hearing aid. Full specifications of the device are detailed in the following Methods
section.
Materials and Methods
The study protocol and supporting TREND checklist are available as supporting
information; see S1 Protocol and S1 TREND Checklist.
Patient screening and selection
After approval from the Human Ethics Committee of the Royal Victorian Eye &
Ear Hospital (application # 11/1032H) and trial registration (www.clinicaltrials.
gov, trial # NCT01603576), three subjects aged 49, 52 and 63 years were enrolled
in the study. Subjects were identified through a screening process at the Centre for
Eye Research Australia, where 95 people with RP participated in a series of
research projects as part of Bionic Vision Australia’s development of the bionic
eye.
An extensive battery of screening tests was used to assess suitability for the
study, including visual performance tests (visual acuity, movement discrimina-
tion, Goldmann visual fields), confirmation of diagnosis through medical reports
and clinical examination, measurement of residual retinal function using
advanced Fourier transform analysis of electroretinography [28], assessment of
the retina and choroidal structure using optical coherence tomography [22],
assessment of functional vision in the home environment by an orientation and
mobility instructor and an optometrist, psychosocial screening tests (including
assessments of quality of life [29]) and a comprehensive consultation with a
rehabilitation psychologist.
Initially, patient informed consent was provided for an 18-month study, but
due to the successful progress in the first year (reported in this paper) and the
availability of new hardware to enhance patient testing, a 6-month extension was
offered to all participants at the twelve-month mark. All participants reconsented
to the extension, making the entire study two years in duration. The second half of
the study, including results of mobility testing and device explantation, will be
detailed in a follow-up report. Independent psychological support was provided at
all stages of the study and, in particular, during the informed consent periods.
The inclusion/exclusion criteria for this study are outlined in Table 1.
The three selected subjects provided written consent after being provided with
both audio and electronic versions of the consent information. The subjects were
a 52 year old post-menopausal female with rod-cone dystrophy and approxi-
mately 20 years of light perception vision (P1), a 49 year old male with syndromic
RP (Bardet-Beidl syndrome) and approximately 8 to 10 years of light perception
vision (P2), and a 63 year old male with rod-cone dystrophy and approximately
20 years of light perception vision (P3). All subjects were guide dog users. P2 and
P3 had significant nystagmus, which did affect the ability to obtain high quality
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ocular images. P3 also had controlled epilepsy, for which he was taking valproate
sodium. He was closely monitored by a neurologist during the study, and there
was no evidence that the surgery or device stimulation changed his condition in
any way.
All three subjects were assessed on four separate occasions over a two-year
period prior to recruitment in the study whilst participating in research studies
examining the natural progression of retinitis pigmentosa. The repeated measures
allowed us to ensure that their baseline level of vision was stable, as people with
RP often experience fluctuations in their visual performance [30, 31], and it is
imperative to obtain an accurate baseline assessment of visual function prior to
any vision restoration treatment.
The suprachoroidal retinal prosthesis implant
The device used in this study consisted of an intraocular electrode array (Fig. 2a),
composed of a silicone substrate with 33 platinum stimulating electrodes
(306600 mm diameter, 36400 mm diameter) and 2 large return electrodes
(2000 mm diameter). The electrodes were recessed 50 mm from the silicone
surface. A third return electrode was implanted remotely subcutaneously behind
the ear. The outer ring of stimulating electrodes was ganged together to allow
investigation of the use of hexagonal stimulation [32], meaning that there were a
total of 20 electrodes that could be individually stimulated (Fig. 2c). The array was
19 mm long and 8 mm wide.
The intraocular array was connected by a helical lead wire to a titanium
percutaneous connector (Fig. 2b), which was implanted behind the subject’s ear.
The lead wire was 150 mm long and contained 23 individually insulated
platinum/iridium wires. The 24th wire from the remote platinum return
connected directly to the percutaneous connector.
The percutaneous connector has previously been used in cochlear implant
studies [27] and required similar surgical procedures as the implantation of a
bone-anchored hearing aid. The connector was anchored to the skull using
titanium screws, and protruded through the skin behind the ear (Fig. 2d). The
advantage with the percutaneous connector was that it enabled direct stimulation
of the electrode array via a connecting lead (Fig. 2e), without the need for
implantable electronics. This allowed unparalleled flexibility in the testing
paradigms possible.
Suprachoroidal surgical technique
The surgical procedures for the implantation of the suprachoroidal retinal
implant and the percutaneous connector were developed as an iterative process,
incorporating both cadaver studies (feline and human) and acute and chronic (3
months) implantation in preclinical studies using a feline model [33]. An acute
study was also completed in a human patient who was undergoing enucleation
due to an unrelated ocular condition. This acute study enabled surgeons to trial
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the procedure with an inactive mock device prior to the commencement of the
clinical trial. Full details of the surgical procedures can be found in a previous
publication by Saunders et al [33], and are summarized here.
Table 1. Inclusion/exclusion criteria.
Inclusion Criteria Exclusion Criteria
Aged 18 years or older Any co-existent ocular disease, with the exception of mild cataracts
Either gender Inability to visualize the retina due to corneal or other ocular media
opacities (corneal degenerations, dense cataracts, trauma, lid
malposition)
A confirmed history of outer retinal degenerative disease such as retinitis
pigmentosa or choroideremia
Any ocular condition that predisposes the subject to rubbing their eyes
Remaining visual acuity of bare light perception or less in both eyes Cognitive deficiencies, including dementia or progressive neurological
disease
Functional inner retina (ganglion cells and optic nerve), as shown by the ability
to perceive light and/or a measurable corneal electrically evoked visual
response
Psychiatric disorders, including depression, as diagnosed by a qualified
psychologist
A history of at least 10 years of useful form vision in the worse seeing eye Deafness or significant hearing loss, or the presence of a cochlear
implant
Must be willing and able to comply with the testing and follow-up protocol
demands (preferably residing within 1.5 hours of the investigational site)
Poor general health or pregnancy, which would exclude them from
obtaining a general anesthetic
doi:10.1371/journal.pone.0115239.t001
Fig. 2. The intraocular electrode array of the suprachoroidal device (A) and the entire device (B),
showing the array connected to the percutaneous connector via a helical lead wire. The electrodes on
the intraocular array (C) were numbered for analysis, with the black electrodes (21a to 21m) being ganged to
provide an external ring for common ground and hexagonal stimulation parameter testing. Note electrodes 9,
17 and 19 were smaller (400 mm vs. 600 mm). The percutaneous connector protruded through the skin behind
the ear (D), allowing direct connection to the neurostimulator via a connecting lead (E). The scleral incision
was made 9 mm to 10 mm posteriorly from the sclero-corneal limbus.
doi:10.1371/journal.pone.0115239.g002
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All three operations occurred at the Royal Victorian Eye and Ear Hospital,
Victoria, Australia between May and August 2012, with vitreoretinal surgeons PA,
JY and MM and ENT surgeon RB. General anaesthesia was administered and the
area was prepared near the site of the percutaneous connector by shaving the hair
and sterilizing the location with Betadine. The eye was also prepared with a
Betadine wash. A dummy electrode array and percutaneous pedestal were used at
this early stage of surgery to plan and mark the required incisions.
A curved scalp incision was used to expose the posterior temporalis muscle,
followed by an incision through the muscle to expose a flat section of squamous
temporal bone. The periosteum was dissected from the bony site to allow
attachment of the percutaneous pedestal. A tunnel was created beneath the
temporalis fascia between the percutaneous connector location and the lateral
orbital rim.
A lateral canthotomy was performed and extended towards the ear and an
incision made in the flap for the percutaneous portion of the device. After the
lateral orbital margin was exposed, the periosteum was incised and a flap created.
A lateral orbitotomy was created with 10 mm burrs below the zygomaticofrontal
suture for lead stabilization. The electrode array was loaded into a purpose built
trochar and then passed forward to the lateral canthotomy/lateral orbital margin.
The percutaneous pedestal was secured with self-tapping screws and the external
ground electrode was placed beneath the temporalis periosteum close to the
pedestal.
The scleral incision was made behind the lateral rectus muscle, to use the
muscle to cover the Dacron patch and reduce the risk of exposure. As such, a
temporal peritomy was performed and the lateral rectus muscle identified. Lateral
rectus was disinserted and tied with 6/0 vicryl (Ethicon). The scleral wound
position was marked with diathermy (as decided from preoperative axial length
measurements, ultrasonography and magnetic resonance imaging). The location
of the scleral wound is demonstrated in Fig. 2f. Due to the axial length, globe
dimensions and lateral rectus muscle insertion location, P3 had a more posterior
incision location (10 mm posterior to the sclera-corneal limbus) than P1 and P2
(both 9 mm posteriorly from the limbus). This meant that the electrode array was
placed more temporal from the fovea for P3 than the other subjects. A full
thickness scleral wound was made with a 15 degree blade (Alcon) and the
suprachoroidal space initially dissected with a crescent blade (Alcon), then with a
lens glide (bvi Visitec 581001).
The electrode array was inserted into suprachoroidal space and the superior
wound edge was extended posteriorly in an L shape to allow the lead to exit and
the Dacron patch to sit flat on the globe. This L shaped extension allowed the
device position to be optimized during insertion. The wound was closed with 8/0
nylon (Ethicon) and the Dacron patch sutured to the sclera with 8/0 nylon.
After the scleral wound was closed, the lateral rectus muscle was reattached. The
device position was assessed with indirect ophthalmoscopy. Due to the subretinal
hemorrhage noted three days postoperatively in P1, we attempted to minimize eye
movements in P2 and P3 in the immediate post-operative recovery period by
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injecting Botulinum toxin Type A (Allergan Australia, NSW, Australia) into the
four extraocular rectus muscles. This did not change the outcome for P2 and P3,
with both also experiencing a mild to moderate subretinal bleed in the 3–4 day
postoperative window.
At the conclusion of the surgery, the conjunctiva was closed with 8/0 vicryl. The
lead was fixated in an orbitotomy drilled in the frontal process of the zygomatic
bone, and held in place by a specifically designed silicone grommet. The
periosteum was closed over this with 6/0 vicryl sutures. The subcutaneous tissue
wound was closed with 6/0 vicryl and the skin sutured with 5/0 nylon or staples.
An injection of subtenon’s local anaesthesia was used for short-term pain relief
and chloramphenicol antibiotic ointment was applied to the eye. Finally, a
pressure dressing was applied to the area surrounding the percutaneous
connector. This was removed the following day.
Subjects remained in hospital for four to five days of postoperative care before
being discharged. They were given postoperative topical steroid (predneferin
forte) and antibiotic (chloramphenicol) eye drops, and analgesia as required. After
discharge, subjects were reviewed weekly and monitored for adverse events, post-
operative safety and clinical efficacy as described below.
Assessment of surgical safety and efficacy
Intraoperative safety was defined as the number of adverse events during the
surgical procedure. Surgical efficacy was defined as the proximity of the electrode
array to the fovea following implantation, and the mechanical stability of the
device in the suprachoroidal space. Both of these assessments were made from
quantitative measurements on ocular imaging modalities (fundus photographs
and optical coherence tomography).
Assessment of post-operative safety
Post-operative safety was assessed by the number of serious device related adverse
events following the implantation. We defined a serious adverse event as one that
required altered or increased medical management, such as surgery or
hospitalization. To be considered as ‘‘device-related’’ there needed to be a direct
or indirect causal link between the device, implantation surgery or study protocols
and the adverse outcome.
Assessment of device and clinical efficacy
Device efficacy was determined by the number of electrodes that remained
connected and viable after implantation (as indicated by electrode impedances)
and the ability for subjects to perceive repeatable phosphenes when the device was
stimulated.
Electrode impedance was measured at the end of the cathodic (first) phase of a
biphasic current pulse and defined as the quotient of dividing the peak measured
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voltage by the supplied current [34]. Individual electrode impedances were
measured using clinical software running on a laptop PC. Measurements were
made intraoperatively to ensure that the implant was functional before closing the
surgical wounds. After surgical recovery, impedance measurements were made
using the same laptop-based system approximately fortnightly for the duration of
the study.
Visual function was assessed via two tests – the Basic Assessment of Light and
Motion (BaLM) test [35] and the Landolt C optotype recognition subtest from the
Freiburg Acuity and Contrast Test (FrACT) [36], both of which were presented to
subjects in a darkened room (108–114 lux) using a 30-inch computer monitor
placed at 57 cm viewing distance. The BaLM test was completed with all subjects,
but only P1 completed the Landolt C testing protocol in the initial 12-month
post-operative period. Testing incorporated a head-mounted video camera with a
manufacturer stated field-of-view of 67˚650.25˚ (Arrington Research Inc.,
Scottsdale AZ, USA) and a pixel dimension of 320 by 240 pixels. Within the
implant, the 20 stimulating electrodes are arranged in a staggered grid measuring
3.5 mm63.46 mm, corresponding to a visual field projection on the retina of
12.4˚612.2˚ [37].
The BaLM test involves detection of a light wedge in one of four quadrants, and
assesses the ability of the device to improve light localisation skills [35]. Given the
response options were four alternative forced choices (4AFC), the chance rate was
25% and the criterion cutoff for success set at 62.5%. The BaLM was completed
with the device off (control) and device on. The device on setting used a vision
processing algorithm called Lanczos2 filtering, which is reported in detail
elsewhere [38, 39]. In short, the Lanczos2 filter is a reconstruction filter that is
used in downsampling and translating the high resolution image from the camera
to electrode stimulation parameters. The filter ensures artefacts from such
downsampling do not appear, such as a flickering which may result from making
small head movements with the camera viewing fine detail. This makes objects
appear more consistent in their appearance. The percentage of accurate responses
in the BaLM test was determined for each participant with device on and device
off. Comparisons between participants and device setting for percentage of
accurate responses were calculated using x2 statistics. Binomial distributions were
calculated to determine whether the accuracy rates were significantly better than
chance (i.e., 25%). Windows SPSS v22 (IBM Corporation, Somers, NY) was used
for all statistical analyses.
The Landolt C optotype recognition test used was a subtest from the FrACT
[36], which is freely available online (http://michaelbach.de/fract/index.html).
This task requires subjects to identify the orientation of a letter C, and can be used
to estimate visual acuity. It was not possible to present appropriately sized
optotypes on our 30-inch computer monitor, so a region-of-interest was defined
within the camera video image to be 18618 pixels, corresponding to a reduced
visual field of 3.77˚63.77˚ (a ‘zoom’ of 3.26). Measured thresholds have this
correction factor applied. The theoretical acuity for this device was assumed to be
the minimum grating distance that can be represented in four orientations. This is
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limited by the 1 mm horizontal electrode spacing, and corresponds to a grating of
0.141 cycles-per-degree, or 2.33 logMAR (20/4242). We only completed the
Landolt C test on P1, and she was tested over 32 sessions. In total, this testing
involved 19 trials with the device on (using Lanczos2 vision processing filter), and
2 trials with the device off. Due to the obvious floor effect with device off, there
was no need to repeat this further. The patient wore a head-mounted camera that
could be focused on different regions of the screen by adjusting her head azimuth
or elevation. She was trained to find the center of each optotype by first judging
it’s width and height. From this central fixation point, the patient explored
regions in each of the four possible directions, returning to the center each time
and repeating until ready to respond. Descriptive analyses and the non-parametric
Wilcoxon Rank Sum test were performed on the Landolt C data using Windows
SPSS v22 (IBM Corporation, Somers, NY).
Results
Three subjects with profound vision loss from retinitis pigmentosa consented for
implantation; two males aged 49 and 63 years and a 52-year-old post-menopausal
female. They were implanted with the suprachoroidal retinal prosthesis and
percutaneous connector in mid-2012. Follow-up data were available for twelve
months for each subject. Details of the clinical characteristics of subjects, electrode
design/fabrication and surgical procedures are described in full in the methods.
An optical coherence tomography (OCT) cross-sectional scan of the device in
vivo is shown in Fig. 3. Due to the fact that the choroid becomes thinner in late
stages of RP [22], the electrode array is easily visualized between the choroid and
sclera.
Surgical safety and efficacy
Implantation surgeries were performed under general anaesthesia and took three
to four hours, with the duration decreasing between surgeries due to experience.
The surgeries progressed without intraoperative complications. Due to the
choroidal atrophy, the electrode array was easily sighted using conventional
indirect ophthalmoscopy techniques during surgery, which allowed the device to
be placed in the optimal position underneath the macula in all three cases. No
intraocular or suprachoroidal hemorrhage was noted during the surgery.
Postoperative clinical results: Retinal health
The postoperative recovery in all three subjects was similar to other major eye
surgeries with respect to reported pain levels and the use of analgesia. Patient 1
(P1) reported more pain around the percutaneous plug implantation site
(requiring narcotic analgesia with morphine 2.5 mg for the first two days) than P2
and P3, both of whom only required simple analgesia (oral paracetamol 1 g for
the first two days). The level of intraocular inflammation was mild and similar to
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that seen in common procedures such as a retinal detachment repair, and treated
with topical steroid (Prednefrin Forte, Allergan Australia, NSW, Australia) and
antibiotic (Chlorsig, Aspen Pharma, NSW Australia) eye drops four times daily.
There was no change in the intraocular pressure of the three participants over the
duration of the trial, in either the implanted or control eye. One patient (P1)
experienced mild to moderate limitation in the abduction of the implanted eye
following surgery, but this function improved over the duration of the study and
did not cause the patient any functional difficulty nor cosmetic concern.
In all three subjects, a combined subretinal and suprachoroidal hemorrhage
formed three to four days postoperatively, which resolved without any ongoing
complications in P1 and P3. In P2, who experienced a larger hemorrhage than the
others, a fibrotic tissue reaction remained at the temporal end of the implant
following hemorrhage resolution, but this did not affect device efficacy nor cause
complications such as retinal detachment. None of the subjects were taking anti-
coagulant medication during this study. We did attempt to reduce eye movements
in P2 and P3 by using intraoperative botulinum toxin injections into the rectus
muscles and medications to reduce rapid eye movements during sleep, but the
reduced eye movements did not prevent this hemorrhage from forming.
Complete resolution of the hemorrhage took 55 days in P1, 101 days in P2 and 13
days in P3. Fundus photos showing the time course of the haemorrhage resolution
for P1 are shown in Fig. 4. None of the subjects required any intervention during
the resolution of the hemorrhage. Testing of the device did not commence until
there was significant resolution of the blood, to allow clear visualization of the
retina prior to any stimulation.
Longitudinal OCT measurements taken over the 12 month post-operative
period demonstrated that there was no change in the retinal thickness above the
electrode array, suggesting that no significant retinal oedema or atrophy had
occurred after the implantation of the array (Fig. 5). Measurements of retinal
thickness were taken directly above each of the 33 stimulating platinum
electrodes, and the results shown reflect the data from all points. Note that as P2
and P3 had significant nystagmus, there was greater variability in the
Fig. 3. OCT scan of the electrode array in situ, taken 2 months postoperatively in Patient 1. The
horizontal arrow on the infrared image indicates the direction of the OCT scan (A). The cross-sectional OCT
image (B) shows the silicone and platinum electrode components of the array, the retina structure and
choroidal vasculature, and the electrode to retina distance used for analysis (double-headed arrow). Scale
bars 5 200 mm.
doi:10.1371/journal.pone.0115239.g003
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measurements due to decreased image quality and the fact that fewer locations
were able to be sampled. Due to persistence of the subretinal and suprachoroidal
hemorrhage in P2, retinal thickness measurements were not possible until Day
143.
Postoperative clinical results: Summary of device-related serious
adverse events
Subjects returned for post-operative assessment on a weekly basis during the
entire study. The only device-related serious adverse event was a staphylococcus
aureus infection around the percutaneous connector in P2 at day 59, which
required a three-day hospital admission. The infection was successfully treated
with a combination of intravenous vancomycin and flucloxacillin, and oral
rifampicin and fusidic acid. The infection did not necessitate removal of the
implant, nor did it have any effect on the stimulation or psychophysics testing. No
device-related serious adverse events occurred with involvement of the intraocular
electrode array.
Postoperative clinical results: Device stability
Intraocular array stability was monitored using fundus photography, infrared (IR)
imaging and OCT. Measurements were taken of the position of the electrode array
with respect to the optic nerve and vascular landmarks, and showed there was no
lateral movement of the array with time. This stability can be seen in the time
series of IR images shown in Fig. 6. Over time the individual electrodes became
more difficult to visualize in P2 and P3.
The distance between the retina and the electrode array was measured from the
cross-sectional OCT scans, and was taken from the anterior surface of the
platinum electrode disc to the posterior surface of the retina (the retinal pigment
epithelium, or RPE), as shown in Fig. 3.
After the subretinal hemorrhage resolved, the electrode to retina distance has
remained relatively constant for P1, but has increased for P2 and P3, Fig. 7. This
increase in separation is visible on OCT scans, which show a hyper-reflective band
Fig. 4. Time course of subretinal hemorrhage in P1, as documented with retinal fundus photography.
Complete resolution of the hemorrhage occurred in this subject by 55 days post-operatively. Note the
electrode array with individual electrodes can be seen more clearly over time as the blood clears in the
temporal retina (arrow).
doi:10.1371/journal.pone.0115239.g004
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between the choroid and the retina. The nature of this band is still under
investigation.
Stability of the titanium percutaneous connector and helical lead wire was
monitored using monthly X-ray images. Comparison of the array and lead wire
position was made with respect to anatomical landmarks, in three primary
positions of gaze (straight ahead, left and right gaze). This also provided
information about physical integrity of the lead wire, which showed no signs of
stress or lead wire breakage. Over this initial twelve-month period, there was no
significant movement of the intraocular array, lead wire or percutaneous
connector on the X-ray images (Fig. 8). Note that the position of the zygomatic
Fig. 5. Retinal thickness measurements over time, showing no observable change in the maximum retinal thickness above the electrode array in
the initial twelve months in all three patients. Each boxplot includes the maximum (upper whisker, excluding outliers), upper quartile (top of box), median
(horizontal line in box), lower quartile (bottom of box) and minimum values (lower whisker). Open circles are outliers. The numbers represent the electrode
location (see Fig. 2), and the horizontal lines on the graph of P3 represent single data points.
doi:10.1371/journal.pone.0115239.g005
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notch varies between subjects, hence there is variability in the vertical position of
the lead entry point in the three subjects. The lead wire formed a broad superior
loop in P1, and followed the temporal wall more closely in P2 and P3.
Postoperative clinical results: Device integrity
Electrode channel continuity was verified by measuring intraoperative and post-
operative electrode impedances. We measured impedance by applying a small test
current pulse and measuring the electrode voltage. The resultant voltage was
divided by the applied current to calculate impedance [40]. In all subjects, 100%
of the electrodes within the implant remained intact following surgery and
remained connected over the twelve-month period.
Electrode impedance data were averaged monthly, from the date of
implantation onwards, for each subject’s array. The distribution of these data are
plotted as box plots (Fig. 9A–C). The mean impedances for the 600 mm electrodes
in P1 and P2 ranged over time from 9.7 to 14.5 kV and for P3 the mean
impedance ranged over time from 3.6 to 13.3 kV. Impedance measurements were
stable over the passive implantation and psychophysics testing periods in P1 & P2,
but decreased significantly in P3 (Fig. 9C). This decrease in impedance suggests a
change in the electrode- tissue interface or in the tissue surrounding the array.
Fig. 6. Time series of IR images of the electrode array in all subjects, showing no significant lateral
movement of the array over a twelve-month period. The leading edge of the array is marked with a white
arrow in the 3-day images. The position of the fovea is marked with a white cross in the 6-month images.
doi:10.1371/journal.pone.0115239.g006
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Further investigation continues to ascertain the exact mechanism of the decreased
impedance for P3.
The range of measured impedances, particularly for P3, included some
markedly low values. However, follow-up device integrity testing (electrode
voltage tomography) on all three subjects did not reveal any evidence of short
circuits in any of the electrode channels, suggesting that these low impedance
values were genuine.
Fig. 7. Distance between the electrodes and retina over time. This distance was relatively constant in P1, but increased up to two-fold in P2 and P3 over
time. Note significant nystagmus in P3 made the measurements difficult, leading to greater variation in the values recorded. Outliers are identified by open
circles, and the numbers represent the electrode location (see Fig. 2).
doi:10.1371/journal.pone.0115239.g007
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Postoperative clinical results: Device efficacy (phosphene
perception)
Following post-operative recovery and allowing time for almost complete
resolution of the hemorrhage over the electrodes, stimulation of the electrode
array commenced for weekly psychophysics sessions of between 2 and 5 hours.
The first stimulation session was held 55 days postoperatively for P1, 87 days for
P2 and at 37 days for P3. Stimulation was delivered using a custom-built
neurostimulator (‘‘neuroBi’’), which allowed direct stimulation of the individual
electrodes via connection with the percutaneous connector [27] and is designed to
allow flexible configuration of testing parameters [41]. The stimulator delivered
charge-balanced biphasic current pulses with pulse widths ranging from 100–
1000 ms per phase. The electrodes were capacitively coupled and shorted between
current pulses to remove any potentially damaging residual charge [42]. Unless
otherwise stated, the electrodes were stimulated in a monopolar electrode
configuration using one of the 2 mm diameter platinum electrodes as the return
(see Fig. 2).
Reliable phosphene percepts were elicited in all three subjects. To ensure that
overstimulation above safe charge and charge density levels did not occur, the
charge per phase on each electrode was capped at 447nC for the 600 mm
electrodes and 298nC for the 400 mm electrodes (which equates to an upper limit
of charge density of 158 mC/cm2 and 237 mC/cm2). These values were determined
Fig. 8. Stability of the intraocular array (arrow) and helical lead wire (star) over the initial 12 months of
implantation, as documented by X-ray images. Additional scans were taken to monitor the percutaneous
connector (not shown), which also stayed stable over this time period.
doi:10.1371/journal.pone.0115239.g008
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using the Shannon model of safe levels for electrical stimulation, using a
conservative k value of 1.85, as defined in Merrill et al [43]. Within this safe charge
limit, percepts were able to be obtained on all 20 electrodes for P1 and 18/20
electrodes for P2 using monopolar stimulation at a rate of 50 pulses per second
(pps). By increasing the stimulation rate to 500pps, percepts could be obtained
from all 20 electrodes in P2.
In P3, it was possible to elicit phosphenes using individual electrodes, however
charge levels approaching the safe limit were required. Stimulation was
subsequently performed using ganged pairs of adjacent electrodes as they
provided greater dynamic range, allowing brighter percepts to be produced
(Fig. 10B). Using ganged pairs increased the maximum safe charge per phase due
Fig. 9. Impedances for the 600 mm platinum electrodes over time in the three subjects. Impedances were measured with charge-balanced biphasic
current pulses (pulse phase width: 25 ms; amplitude: 75 mA). The dotted lines represent the date of first stimulation. In P1 & P2, the impedances were stable
over the implantation and stimulation period. Impedances measured in P3 decreased over the course of the implantation period. Outliers are identified by
open circles, and the numbers represent the electrode location (see Fig. 2).
doi:10.1371/journal.pone.0115239.g009
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to the larger total electrode area, thus enabling a 100% utilization rate for all
ganged pairs tested with P3.
Phosphene appearance was found to be varied depending on subject, electrode
position and stimulation parameters, but were controllable (in terms of size and,
brightness and complexity), retinotopically placed and locatable in the visual field
by the subject [44].
Visual function results: Light localisation
In all subjects, the light localisation sub-task of the Basic Assessment of Light and
Motion (BaLM) test [35] was completed to assess the device’s ability to improve
light localisation. In this test, the subject needs to identify the orientation of a
wedge of light on a black computer screen (up/down/left/right), and it is a four
alternative forced choice paradigm with a chance rate of 25%.
For the device on setting (using a Lanczos2 filter), all three participants
performed significantly better than the 25% chance level. achieving 97.50%
(p,.0001), 71.43% (p,.0001), and 66.66% (p,.0001) correct response rates for
P1, P2 and P3 respectively. All of the participants performed at a level at or below
chance when the vision processing system was switched off; Table 2.
Visual function results: Optotype acuity estimates
As P1 was implanted first, we have results for a longer post-implant time than for
the other two participants. This enabled us to begin to measure optotype
recognition using the Landolt-C task in the FrACT visual test battery [36]. For the
device on setting (using the Lanczos2 filter), visual acuity was estimated to be 2.62
logMAR on average (range 2.35 to 3.02) corresponding to 20/8397 (range 20/4451
to 20/21059) over 19 sessions (Fig. 11). This compares favorably to the calculated
limit of 2.33 logMAR (20/4242) for a 1 mm electrode pitch [37]. For the device
off setting, P1 was unable to see any of the Landolt C optotypes at all. Due to the
limit of the software (floor effect) we were unable to estimate any visual acuity
lower than 3.24 logMAR. The average response time per optotype presentation
was 59 seconds for device on (range 43 to 80 seconds) and 11 seconds for device
off.
The non-parametric Wilcoxon Rank-Sum test was employed to determine
whether there were differences between Lanczos2 vision processing and System
Off in performance for visual acuity (logMAR) using Landolt C optotypes.
Lanczos2 (N519, Median52.70) vision processing performed significantly better
than System Off (N52, Median53.235) for P1 with z522.280, p50.010; Fig. 11].
Discussion
This world-first Phase 1 trial of a retinal implant in the suprachoroidal space has
shown that the novel surgical procedure is safe, the position is stable and the
device was able to provide visual percepts in all three subjects. The electrode array
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was well tolerated by the eye and all electrodes on the three arrays remained
functional over the 12-month monitoring period.
The main advantage with the suprachoroidal surgical approach is the ease and
safety of the surgical procedure, as well as the proven device efficacy in all three of
our subjects. It is remarkable that all electrodes remained functional for our
subjects for the 12-month period, as this has not been the case with previous
devices. For example, a report to the US Food and Drug Administration in
September 2012 reported that in the Argus II 60-electrode device clinical trial, an
average of 55.5¡3.6 electrodes were functioning directly after implant, with
another 1.2¡1.8 electrodes automatically disabled during stimulation due to high
impedances [20].
The implantation surgery for each device took less than four hours, and there
were no intraoperative adverse events in any subject. It is anticipated that the
Fig. 10. Different monopolar electrode stimulations used in the psychophysical testing of the implanted subjects (A & B), where the active
electrodes are shown in red and the return electrodes in black. Table (C) shows the number of electrodes that were capable of eliciting a visual percept
using the given stimulation parameters in each subject. PW5 phase width, IPG5 interphase gap, pps5 pulses per second. Stimulus duration was 2
seconds in all cases.
doi:10.1371/journal.pone.0115239.g010
Table 2. Results of the BaLM light localisation task, showing that using the device (with a Lanczos2 vision-processing filter) gave significant visual
improvement compared with device off, p,0.0001 for all three subjects.















on and device off
P1 40 39 97.5% 72 20 27.78% P,0.0001
P2 56 40 71.43% 40 10 25% P,0.0001
P3 48 32 66.66% 40 10 25% P,0.0001
doi:10.1371/journal.pone.0115239.t002
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surgical procedure used for the implantation of these suprachoroidal devices
could be undertaken by the majority of ophthalmic surgeons, which to date has
not been the case for the other retinal approaches. It is also anticipated that this
location may allow for simpler removal and replacement with upgraded devices in
the future. This has been demonstrated in preclinical feline models [45] but not
yet in humans.
The devices have been mechanically stable over the initial postoperative twelve
months, with no lateral movement (with respect to the retinal vasculature
landmarks) nor signs of extrusion. The one serious device-related adverse event
that did develop in this initial twelve-month period was an infection of the
percutaneous connector, which was an anticipated risk (having been noted in
previous trials using percutaneous connectors for cochlear implant research) and
was successfully treated with intravenous antibiotics with no damage to the
device, nor need for explantation. The use of a percutaneous connector allowed
direct and flexible stimulation of the intraocular electrode array, but required a
metallic foreign body to protrude from the skull for the duration of the study. In
subsequent studies it is planned that the percutaneous connector will be replaced
with a fully implantable and wireless stimulator system, hence eliminating the risk
of such infections in future iterations.
The other adverse event that was noted was that all three subjects had a
combined subretinal and suprachoroidal hemorrhage three to four days post-
operatively, which resolved without complication in two patients. In P2, a small
fibrovascular scar remained at the edge of the implant following haemorrhage
resolution, which has been stable for 12 months. After noting this in our first
subject, the study protocol was changed to include intraoperative botulinum toxin
injection and post-operative oral medication to reduce rapid eye movement
during sleep, in the hope that a more stable eye during the initial healing period
would prevent the formation of this hemorrhage. However, this was not the case,
and the exact mechanism of the hemorrhage remains unclear.
Fig. 11. Optotype recognition results for P1 using the Landolt-C test, which gives an indication of
acuity (but should not be directly interpreted as standard visual acuity). Whiskers extend to minimum
and maximum recorded thresholds and the box extents show inter-quartile range. The Lanczos2 vision
processing performed significantly better than System Off (P5.01). Note that the visual acuity exceeded the
3.24 logMAR software limit in all trials with device off (floor effect).
doi:10.1371/journal.pone.0115239.g011
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Due to the suprachoroidal implant location, we were concerned about the risk
of damaging the long posterior ciliary neurovascular bundle during implantation,
as this bundle pierces the sclera and crosses the suprachoroidal space [46]. We
were prepared for the risk of contacting this bundle with a surgical contingency
plan, which included methods of diathermy to stem any bleeding, as outlined
previously [33]. However, this was not required in any of the patients. Due to the
fact that the postoperative bleeding originated in the anterior choroid (not in the
suprachoroidal space) and occurred in the postoperative period, we do not believe
that this was the cause of the observed hemorrhages. However, the presence of the
long posterior ciliary neurovascular bundle does need to be considered during
suprachoroidal implant surgeries.
As can be seen in the IR images (Fig. 6), the electrodes have become more
difficult to visualize with time, especially in P3. This is correlated with an increase
in the electrode to retina distance in P3. This may be due to a change in the tissue-
electrode interface, but due to limitations in ocular imaging techniques associated
with the subject’s nystagmus, we cannot conclusively determine whether this area
is fibrous tissue, fluid or some other material. Ongoing investigations are
continuing, and it is likely that we will need to wait until explantation of the
devices to gain further information. This outcome was not noted in our
preclinical feline models.
Intra-operative and post-operative impedance testing demonstrated ongoing
electrode continuity over a twelve-month follow-up period. These results suggest
a robust electrode array, lead system and connector. This is a significant finding,
as it is very common for some electrodes and even the lead wires to break during
implantation surgery in other locations. In addition to demonstrating surgical
safety, the fact that all electrodes within the clinical arrays were viable after twelve
months implantation shows the mechanical robustness and stability of the
suprachoroidal position and associated lead routing path.
Another interesting finding has been the decrease in impedances in P3 over
time. Whilst P1 and P2 maintained a mean impedance of 9.7–14.5 kV over the
study period, impedances for P3 dropped from an initial mean measure of
13.3 kV to a mean of 3.6 kV by twelve months. A drop in impedance suggests a
change in the electrode-tissue interface or the tissue surrounding the array, but the
exact cause for these changes are not known, with further investigations underway
to ascertain the potential mechanism.
The impedance results are comparable to those derived from previous studies
in our feline model, using a similar suprachoroidal position for the electrode array
with platinum electrodes of the same dimensions [40]. These preclinical studies
showed stable mean impedances in the range of 11–15 kV over a 5 month
implantation period with approximately three months of continuous supra-
threshold electrical stimulation in the suprachoroidal space. The similarity
between impedances measured clinically and preclinically adds support to the
veracity of the feline suprachoroidal model published previously by our group,
which will be used for ongoing development of future devices.
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We were able to generate visual percepts in all three subjects within a safe
charge limit. It was necessary to use ganged pairs of electrodes to gain useful
percepts with a satisfactory dynamic range for P3, which may be due to the
increased distance between the array and the retina, or due to the array being
further from the macula than in the other two subjects (see Fig. 6). Unlike the
other two participants, P3 is also on anti-epileptic medication (valproate sodium
100 mg), which potentially may have a role determining the parameters needed to
record a percept. Further details on the factors that affect phosphene perception in
this cohort are detailed in a separate publication by Shivdasani et al [47].
As this was an initial proof of concept study, with only three participants were
recruited, it was not possible to draw inferences about the effect of gender, age,
surgical ancillary treatment (i.e. the use of Botox injections during implantation)
or systemic medications on the outcomes. It is certainly of interest that the results
varied between our three participants, and this gives support to our belief that
device fitting and outcome assessment for bionic eyes will remain a time-
consuming and individual process.
Device efficacy was also shown using a test of light localisation (BaLM test) and
a Landolt-C optotype recognition test (FrACT test). Light localisation is a simpler
visual function than optotype recognition, but does not enable an estimate of
visual acuity. We demonstrated that all subjects showed improved light
localisation with the device on (all passing the test’s ‘‘pass’’ criterion of 62.5%),
with performance with device off below the level of chance. We found that the
Landolt-C test required significant orientation and habituation, which was not
possible in the 12-month postoperative time frame for P2 and P3. As P1 was
implanted first, we were able to estimate her optotype acuity using this test, and
showed that it was significantly improved with device on (best logMAR
measured52.35) vs. device off (logMAR worse than 3.24, reached the floor effect
of the test). Previously reported visual acuity from other groups have been up to
20/1262 (logMAR 1.8) for the Argus II epiretinal device (60 electrodes) using
grating acuity tests [15] and 20/546 (logMAR 1.43) for the Retina Implant AG
Alpha IMS device (1500 independent microphotodiode-amplifier-electrode
elements) using the Landolt C optotype acuity test [48].
It should be noted that the use of Landolt C optotype recognition tests in
prosthetic vision gives estimations of acuity only, and cannot be directly
compared with acuity tests in normally sighted individuals. Subjects with a visual
prosthesis will use different techniques to assess the optotypes, including head
scanning and learnt interpretation of the phosphenes. Thus the visual acuity
reported using visual prostheses is likely to be overestimated. Future studies will
be vital to obtain more detailed information regarding the potential visual acuity
of the suprachoroidal devices in a greater number of participants, and this
estimated acuity value should be interpreted with caution, and whilst
remembering that our prototype device only had 20 stimulating electrodes.
This study has shown the suprachoroidal anatomical position is a viable,
minimally invasive and relative straightforward location for an electrode array,
with successful stimulation of visual percepts and excellent lateral device stability
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in all subjects. The device efficacy is expected to improve with technological
advances in the next iteration, and also with the ability for patients to be trained
on use in their home environment in future trials (which was not possible in this
study). We will continue to investigate the presence of the band between the
device and choroid, including using histopathological assessment techniques on
explanted devices at the end of this study (which will cease in late 2014). The
inherent advantages of the suprachoroidal position, including ease of surgery (no
vitrectomy or retinal incision required), robustness and stability of the electrodes,
and minimal implant-related intraocular serious adverse events suggest that this
approach has promise in the field of retinal prosthesis research.
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